Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780804 · ClinicalTrials.gov registry record · Phase 1
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 20
- Study locations
NCT02780804: Completed Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by National Cancer Institute (NCI).
NCT02780804 is a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02780804, a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.
Primary Outcome
The MTD/RP2D will be defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity during cycle 1 of therapy among 6 toxicity-evaluable patients. The frequency of cycle 1 dose limiting toxicities will be summarized by dose level among patients in the dose escalation part of the study.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Entinostat
- OTHER Pharmacological Study
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Medical Center-Mission Bay - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Egleston - Atlanta
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 1 |
What the finished NCT02780804 record still lists
NCT02780804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (67% lower).
The record links to 10 conditions, with Refractory Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02780804 names 20 study sites across 17 states, led by California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT02780804 about?
NCT02780804 is a clinical study titled "Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors". This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.
What is the current status of trial NCT02780804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-01-06. Estimated completion is 2021-09-30.
What conditions does trial NCT02780804 study?
This clinical trial studies the following conditions: Refractory Malignant Solid Neoplasm, Refractory Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Lymphoma, Recurrent Primary Central Nervous System Neoplasm.
What interventions are being tested in trial NCT02780804?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Entinostat (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02780804?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02780804 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02780804's enrollment target sits among peer trials
21 50th of 59 higher than 10 of 59 other Refractory Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
RECRUITING · Phase 1
-
AOH1996 for the Treatment of Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI